Magnetic Resonance Imaging Findings In The Brain Of Patients With Cerebrotendinous Xanthomatosis
Published on: December 11, 2025
Magnetic Resonance Imaging Findings In The Brain Of Patients With Cerebrotendinous Xanthomatosis
  • Article author photo

    Selwyn Barreto

    Bachelors of Science in Medical Laboratory Technology , Clinical Laboratory Science/Medical Technology/Technologist, Nitte University

  • Article reviewer photo

    Adriana Anton

    PhD in Biomedical Physics, Master of Science in Biomedical Physics

Introduction

Cerebrotendinous xanthomatosis (CTX) is an inherited metabolic disorder caused by mutations in the CYP27A1 gene, leading to defective bile acid1 synthesis and pathological accumulation of cholesterol and cholestanol in tissues, including the brain. This silent intruder shapes the body and mind, appearing first with subtle symptoms in childhood and progressing to severe neurological and psychiatric manifestations in adulthood.2 Magnetic resonance imaging (MRI) is indispensable in unveiling the hidden effects of CTX in the brain, offering non-invasive insights into diagnosis, prognosis, and treatment guidance.3,4

Understanding CTX: the silent intruder

CTX often begins early, manifesting as chronic diarrhoea, cataracts, and tendon xanthomas. As the disease advances, it disrupts the nervous system with mental slowness, ataxia, spasticity, and psychiatric changes, including depression, agitation, and hallucinations.1,2 The defect in the CYP27A1 gene interrupts bile acid synthesis, resulting in the abnormal buildup of sterols within nerve tissue.1,2,3

Why MRI is essential in CTX

MRI is the gold standard for visualising the brain's structure and detecting soft tissue abnormalities in CTX.4 Its benefits include:

  • Non-invasive, radiation-free imaging
  • Sensitive detection of localised and diffuse brain changes
  • Identification of early microstructural alterations
  • Tracking disease progression and therapy response

MRI does not just help diagnose CTX; it monitors how the disease changes over time and how it responds to treatment.4

Classical MRI findings in CTX

Bilateral symmetrical lesions in the dentate nuclei and cerebellum

The hallmark MRI feature of CTX is bilateral, symmetrical hyperintense lesions in the dentate nuclei of the cerebellum, best seen on T2-weighted and fluid-attenuated inversion recovery (FLAIR) images.4, 5, 6

  • Dentate nuclei:

Crucial for motor coordination; lesions here cause ataxia and speech disturbances.

  • Hyperintense signals: 

Indicate demyelination and axonal degeneration.

  • T2 hypointense rim: 

Occasionally seen, marking boundaries of lipid-laden foam cells.

Supratentorial white matter abnormalities

CTX frequently causes hyperintense signals in the periventricular and deep cerebral white matter, affecting regions such as:

These reflect widespread demyelination, resulting in cognitive decline, motor impairments, and psychiatric features.1,7,8

Brain atrophy: cerebral and cerebellar

MRI may show shrinkage of the cerebral cortex and cerebellum (atrophy), correlating to duration and severity of symptoms.1

Early-onset cases:

Often display mild or equivocal atrophy.

Late-onset cases: 

Exhibit more severe atrophy, both cerebral and cerebellar.

Other regions: olivary nucleus, pyramidal tracts, optic nerves

Less common findings include hypertrophic olivary degeneration, changes in pyramidal tracts, basal ganglia involvement, and, occasionally, optic nerve swelling. These contribute to vision disturbances and movement disorders.

Advanced MRI techniques: spectroscopy and diffusion

  • Magnetic resonance spectroscopy (MRS):

Shows biochemical changes such as decreased N-acetylaspartate (NAA), increased choline, and lactate concentrations, signs of neuronal loss and mitochondrial dysfunction.6

  • Diffusion-weighted imaging (DWI):

Highlights areas of demyelination and subtle axonal damage.7,9,10

The pathological basis behind MRI findings

All these imaging abnormalities stem from the accumulation of cholestanol and cholesterol, triggering:

  • Demyelination: 

Loss of myelin sheath, impairing nerve transmission.

  • Axonal degeneration: 

Leaves behind glial scars and hollow brain cavities.

  • Xanthoma formation: 

Lipid-laden macrophages cluster in affected areas.

Clinical correlation: linking images to symptoms

The alignment of MRI findings with clinical symptoms is striking:

  • Dentate nucleus lesions: Ataxia and speech disturbance
  • White matter abnormalities: Cognitive decline, dementia, psychiatric issues
  • Cerebellar atrophy: Gait instability, motor incoordination
  • Basal ganglia/thalamic changes: Movement disorders, rigidity

MRI often detects silent brain damage, making it essential for early diagnosis—even before the appearance of neurological symptoms.

Diagnostic process: step-by-step in CTX

  • Suspicion: 

Recurrent diarrhoea, cataracts, tendinous masses, and neuropsychiatric symptoms.

  • Initial MRI: 

Symmetrical T2/FLAIR hyperintensities in dentate nuclei and cerebellar white matter.

  • Other imaging: 

Seek diffuse or focal white matter changes, atrophy, or abnormal signals in supratentorial regions.

  • Spectroscopy/MRS: 

Confirms metabolic dysfunction6

  • Laboratory: 

Elevated cholestanol, confirmed by genetic testing for CYP27A1 mutations.

Case studies: imaging tells the story

Case 1: Early-onset CTX

A 32-year-old patient with chronic diarrhoea, cataracts, and tendon xanthomas. MRI reveals bilateral hyperintense signals in the dentate nuclei, mild cerebellar atrophy, and patchy supratentorial white matter lesions. CDCA therapy halts disease progression.

Case 2: Late-onset CTX

A 63-year-old patient presents with progressive dementia and gait disturbance. MRI shows severe cerebral and cerebellar atrophy, widespread white matter changes, and symmetric dentate nucleus involvement. Diagnosis confirms advanced CTX.

Case 3: Pediatric CTX

A 10-year-old patient with developmental delay and xanthomas has mild MRI changes, focal dentate nucleus hyperintensity, minimal cerebral atrophy, and scattered supratentorial lesions. Early diagnosis and treatment stabilise the disease for over five years.

Longitudinal MRI insights: tracking CTX over time

MRI abnormalities progress in patients diagnosed after age 24 but remain stable in those treated before 24. Chenodeoxycholic acid (CDCA) therapy prevents further degeneration.8

  • MRI can detect preclinical disease, guiding proactive intervention.
  • Regular follow-up MRI helps monitor therapy response and disease stability.

Differential diagnoses: avoiding missteps

MRI features in CTX are reminiscent of other metabolic and leukodystrophic disorders, such as metronidazole toxicity or maple syrup urine disease. Key distinguishing clues are:

  • Preference for dentate nucleus involvement
  • Presence of tendon xanthomas, usually Achilles
  • Elevated cholestanol/cholesterol levels
  • Clinical triad: diarrhoea, cataract, ataxia 

Combining MRI findings with clinical and biochemical investigations ensures accurate diagnosis.

Prognosis and therapy: what MRI can tell us

MRI findings help forecast outcomes, guide early therapy, and track responses:

  • Chenodeoxycholic acid (CDCA) supplementation: 

Restores normal bile acid metabolism, halts further deposition, and stabilises MRI changes.3 Early and consistent treatment is the key to preventing irreversible symptoms and improving life quality.

  • Statins: 

Sometimes used to manage cholesterol.

  • Improvements seen on MRI reinforce ongoing therapy.

Early diagnosis and therapy are tied to significantly better outcomes. Untreated CTX progresses to severe neurological and psychiatric symptoms and shortened lifespan.

Impact on patients and families

MRI not only clarifies CTX's hidden progression but also empowers clinicians, patients, and families to take charge of diagnosis and management. Awareness of MRI findings can reduce anxiety, enable informed choices, and foster hope for recovery.

Frequently asked questions (FAQ)

Q1. What is CTX, and why does it affect the brain?

CTX is a genetic disorder interfering with bile acid synthesis; cholesterol and cholestanol accumulate in the brain, causing damage to nerves and cerebral tissue.

Q2. What are the most characteristic MRI findings in CTX?

Bilateral symmetrical hyperintense lesions in the dentate nuclei, cerebellar and cerebral atrophy, and supratentorial white matter changes are most common.

Q3. How is CTX diagnosed?

Diagnosis involves clinical evaluation, laboratory tests measuring cholestanol, genetic confirmation of CYP27A1 variants, and MRI of the brain to assess neurological involvement.

Q4. How is CTX managed?

CDCA is the primary treatment; statins may also be used. Dietary changes, surgeries for tendon xanthomas or cataracts, and careful monitoring are essential.

Q5. What is the prognosis for CTX patients?

With early diagnosis and regular CDCA therapy, patients can achieve a normal or near-normal lifespan. Untreated disease can lead to severe neurological disability and early death.

Q6. Can MRI findings improve with treatment?

Yes! Early, consistent CDCA therapy stabilises or even improves MRI findings, especially if started before significant neurological damage occurs.

Q7. Why is early diagnosis important?

Because once neurological damage occurs, it may be irreversible. Early MRI and clinical suspicion allow for therapy before the disease progresses.

Summary

  • CTX is a treatable neurodegenerative disease with a spectrum of symptoms
  • MRI is vital for early diagnosis, prognosis, and therapy monitoring
  • Key MRI features include bilateral dentate nucleus lesions, supratentorial white matter abnormalities, cerebellar and cerebral atrophy, and T2 hypointense rims
  • Timely CDCA therapy can halt disease progression and stabilise MRI findings
  • MRI detects both apparent and silent brain damage, supporting patient-centred care from diagnosis through long-term management

References

  1. 1. Ho ML, Sharma R, Knipe H. Cerebrotendinous xanthomatosis. In: Radiopaedia.org [Internet]. Radiopaedia.org; 2009 [cited 2025 Sep 15]. Available from: https://radiopaedia.org/articles/7279. 
  2. Nóbrega PR, Bernardes AM, Ribeiro RM, Vasconcelos SC, Araújo DABS, Gama VCDV, et al. Cerebrotendinous Xanthomatosis: A practice review of pathophysiology, diagnosis, and treatment. Front Neurol [Internet]. 2022 Dec 23 [cited 2025 Sep 15];13:1049850. Available from: https://www.frontiersin.org/articles/10.3389/fneur.2022.1049850/full.
  3. Ma C, Ren YD, Wang JC, Wang CJ, Zhao JP, Zhou T, et al. The clinical and imaging features of cerebrotendinous xanthomatosis: A case report and review of the literature. Medicine [Internet]. 2021 Mar 5 [cited 2025 Sep 16];100(9):e24687. Available from: https://journals.lww.com/10.1097/MD.0000000000024687. 
  4. Mignarri A, Dotti MT, Federico A, De Stefano N, Battaglini M, Grazzini I, et al. The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression. J Neurol [Internet]. 2017 May [cited 2025 Sep 16];264(5):862–74. Available from: http://link.springer.com/10.1007/s00415-017-8440-0. 
  5. Gaillard F, Campos A, Hacking C. Dentate nucleus. In: Radiopaedia.org [Internet]. Radiopaedia.org; 2016 [cited 2025 Sep 15]. Available from: https://radiopaedia.org/articles/49083. 
  6. De Stefano N, Dotti MT, Mortilla M, Federico A. Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain [Internet]. 2001 Jan [cited 2025 Sep 16];124(1):121–31. Available from: https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/124.1.121. 
  7. Dell’Aversano Orabona G, Dato C, Oliva M, Ugga L, Dotti MT, Fratta M, et al. Multi-imaging study in a patient with cerebrotendinous xanthomatosis: radiology, clinic and pathology correlation of a rare condition. BJR|case reports [Internet]. 2020 Mar [cited 2025 Sep 19];6(1):20190047. Available from: https://academic.oup.com/bjrcr/article/7244062. 
  8. Stelten BML, Lycklama À Nijeholt GJ, Hendriks E, Kluijtmans LAJ, Wevers RA, Verrips A. Long-term mri findings in patients with cerebrotendinous xanthomatosis treated with chenodeoxycholic acid. Neurology [Internet]. 2022 Sep 27 [cited 2025 Sep 19];99(13):559–66. Available from: https://www.neurology.org/doi/10.1212/WNL.0000000000201112. 
  9. Chang CC, Lui CC, Wang JJ, Huang SH, Lu CH, Chen C, et al. Multi-parametric neuroimaging evaluation of cerebrotendinous xanthomatosis and its correlation with neuropsychological presentations. BMC Neurol [Internet]. 2010 Dec [cited 2025 Sep 19];10(1):59. Available from: http://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-10-59.
  10. Inglese M, De Stefano N, Pagani E, Dotti MT, Comi G, Federico A, Filippi M. Quantification of brain damage in cerebrotendinous xanthomatosis with magnetization transfer MR imaging. AJNR Am J Neuroradiol. 2003 Mar;24(3):495-500. PMID: 12637303; PMCID: PMC7973612.
Share

Selwyn Barreto

Bachelors of Science in Medical Laboratory Technology , Clinical Laboratory Science/Medical Technology/Technologist, Nitte University

Selwyn Barreto is a Biomedical Scientist and Medical Laboratory Technologist with a strong foundation in microbiology and clinical pathology. Holding a Bachelor of Science in Medical Laboratory Technology, he is registered with the Health and Care Professions Council (HCPC) and the Christian Medical Association of India (CMAI). Selwyn specializes in RTPCR testing, bacterial culture, and ELISA testing. As a Healthcare Article Writer at Klarity, he creates engaging and accurate medical content for diverse audiences. His certifications include Infection Prevention and Control from the World Health Organization. Outside the laboratory, Selwyn is proficient in Microsoft Office, Google Drive, and graphic design using Photoshop. His interests in music, photography, sketching, and gaming reflect his well-rounded personality.

arrow-right